Abstract
Linked Articles: This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381. The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.
Original language | English (US) |
---|---|
Pages (from-to) | 455-465 |
Number of pages | 11 |
Journal | British Journal of Clinical Pharmacology |
Volume | 83 |
Issue number | 3 |
DOIs | |
State | Published - 2017 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 The British Pharmacological Society
Keywords
- cardiotoxicity
- childhood cancer
- dexrazoxane
- survivor